Evidence map›Paper›PMID 40322679›Full record

ArticleClinical kidney journal2025

Long-term evaluation of the timing of corticosteroid therapy in an IgA nephropathy cohort.

Wanyin Hou, Haiyan Yang, Pei Chen, Chen Tang, Xujie Zhou, Lijun Liu, Li Zhu, Sufang Shi, Jicheng Lv, Hong Zhang

Abstract read
In one paragraph

Article in Clinical kidney journal, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Wanyin HouRenal Division, Department of Medicine, Peking University First Hospital, Institute of Nephrology, Peking University, Key Laboratory of Renal Disease, Ministry of Health of China, Beijing, China.
Haiyan YangDepartment of Nephrology and Rheumatology, Zunyi Hospital of Traditional Chinese Medicine, Zunyi, Guizhou, China.
Pei ChenRenal Division, Department of Medicine, Peking University First Hospital, Institute of Nephrology, Peking University, Key Laboratory of Renal Disease, Ministry of Health of China, Beijing, China.
Chen TangRenal Division, Department of Medicine, Peking University First Hospital, Institute of Nephrology, Peking University, Key Laboratory of Renal Disease, Ministry of Health of China, Beijing, China.ORCID https://orcid.org/0000-0002-7225-9105
Xujie ZhouRenal Division, Department of Medicine, Peking University First Hospital, Institute of Nephrology, Peking University, Key Laboratory of Renal Disease, Ministry of Health of China, Beijing, China.
Lijun LiuRenal Division, Department of Medicine, Peking University First Hospital, Institute of Nephrology, Peking University, Key Laboratory of Renal Disease, Ministry of Health of China, Beijing, China.
Li ZhuRenal Division, Department of Medicine, Peking University First Hospital, Institute of Nephrology, Peking University, Key Laboratory of Renal Disease, Ministry of Health of China, Beijing, China.
Sufang ShiRenal Division, Department of Medicine, Peking University First Hospital, Institute of Nephrology, Peking University, Key Laboratory of Renal Disease, Ministry of Health of China, Beijing, China.
Jicheng LvRenal Division, Department of Medicine, Peking University First Hospital, Institute of Nephrology, Peking University, Key Laboratory of Renal Disease, Ministry of Health of China, Beijing, China.
Hong ZhangRenal Division, Department of Medicine, Peking University First Hospital, Institute of Nephrology, Peking University, Key Laboratory of Renal Disease, Ministry of Health of China, Beijing, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background: Current proposed KDIGO guidelines suggest systemic corticosteroid therapy to reduce glomerular inflammation in immunoglobulin A nephropathy (IgAN), however the optimal timing for initiating steroid treatment remains a topic of debate. This study evaluates the impact of early versus delayed steroid initiation on long-term outcomes in IgAN patients. Methods: We conducted a retrospective study of 268 IgAN patients treated with corticosteroids for >3 months within 3 years of kidney biopsy. Patients were categorized into early therapy (steroids within 30 days) and delayed therapy (after 30 days). Propensity score matching created matched cohorts. Kaplan-Meier curves and Cox regression assessed outcomes. The primary endpoint was a composite renal outcome [estimated glomerular filtration rate (eGFR) >50% reduction, end-stage kidney disease or renal death]. Secondary endpoints included eGFR decline >30% or >40% and an eGFR slope and time-average proteinuria. Results: Propensity score matching identified 191 individuals for analysis. The primary outcome was significantly better in the early therapy group, with a hazard ratio (HR) of 0.41 [95% confidence interval (CI) 0.17-0.96, Conclusions: Early corticosteroid therapy may help reduce renal decline and preserve long-term kidney function in IgAN patients requiring steroid treatment.

Indexed as

corticosteroidIgA nephropathytimingtreatment

Identifiers

PMID40322679
PMCPMC12044332

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.